323 related articles for article (PubMed ID: 29499075)
1. Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer.
Dall'Era MA; Lo MJ; Chen J; Cress R; Hamilton AS
Cancer; 2018 May; 124(9):1921-1928. PubMed ID: 29499075
[TBL] [Abstract][Full Text] [Related]
2. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer.
Jang TL; Patel N; Faiena I; Radadia KD; Moore DF; Elsamra SE; Singer EA; Stein MN; Eastham JA; Scardino PT; Lin Y; Kim IY; Lu-Yao GL
Cancer; 2018 Oct; 124(20):4010-4022. PubMed ID: 30252932
[TBL] [Abstract][Full Text] [Related]
4. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.
Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ
Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182
[TBL] [Abstract][Full Text] [Related]
5. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.
Yang DD; Mahal BA; Muralidhar V; Boldbaatar N; Labe SA; Nezolosky MD; Vastola ME; Beard CJ; Martin NE; Mouw KW; Orio PF; King MT; Nguyen PL
Cancer; 2017 Dec; 123(24):4832-4840. PubMed ID: 28832984
[TBL] [Abstract][Full Text] [Related]
6. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
7. Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
Sooriakumaran P; Nyberg T; Akre O; Widmark A; Hamdy F; Graefen M; Carlsson S; Steineck G; Wiklund NP
Eur Urol; 2017 Sep; 72(3):345-351. PubMed ID: 28416350
[TBL] [Abstract][Full Text] [Related]
8. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
[TBL] [Abstract][Full Text] [Related]
9. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study.
Stattin P; Sandin F; Thomsen FB; Garmo H; Robinson D; Lissbrant IF; Jonsson H; Bratt O
Eur Urol; 2017 Jul; 72(1):125-134. PubMed ID: 27481175
[TBL] [Abstract][Full Text] [Related]
10. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
[TBL] [Abstract][Full Text] [Related]
11. Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
Patel DN; Jha S; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Chapin BF; Freedland SJ
Int J Urol; 2018 Dec; 25(12):998-1004. PubMed ID: 30253446
[TBL] [Abstract][Full Text] [Related]
12. Locally advanced prostate cancer: effective treatments, but many adverse effects.
Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Local and Systemic Therapy for T4 Prostate Cancer.
Kim AH; Konety B; Chen Z; Schumacher F; Kutikov A; Smaldone M; Abouassaly R; Khanna A; Kim SP
Urology; 2018 Oct; 120():173-179. PubMed ID: 29990574
[TBL] [Abstract][Full Text] [Related]
14. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
15. Survival and secondary interventions following treatment for locally-advanced prostate cancer.
Sussman R; Carvalho FLF; Harbin A; Zheng C; Lynch JH; Stamatakis L; Hwang J; Williams SB; Hu JC; Kowalczyk KJ
Can J Urol; 2018 Oct; 25(5):9516-9524. PubMed ID: 30281010
[TBL] [Abstract][Full Text] [Related]
16. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
17. Survival following primary androgen deprivation therapy among men with localized prostate cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
JAMA; 2008 Jul; 300(2):173-81. PubMed ID: 18612114
[TBL] [Abstract][Full Text] [Related]
18. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
Sammon JD; Abdollah F; Reznor G; Pucheril D; Choueiri TK; Hu JC; Kim SP; Schmid M; Sood A; Sun M; Kibel AS; Nguyen PL; Menon M; Trinh QD
Eur Urol; 2015 Jul; 68(1):32-9. PubMed ID: 25457017
[TBL] [Abstract][Full Text] [Related]
20. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
